Page 5 - Glenmark Pharmaceuticals

Glenmark Life IPO subscribed 2.8x on Day-1 on strong retail interest

The wholly-owned subsidiary of Glenmark Pharma is issuing Rs 1,060 cr fresh equity and offer for sale of 6.3 million shares worth Rs 453.6 crore

Street signs: Glenmark Life GMP at 25%, HNIs in-the-money in Tatva & more

Analysts say American sanctions on Chinese companies will prompt global investors to look at India more favourably

Glenmark Life Sciences prices its IPO between Rs 695-720 per share

The company has reduced its offer size by about Rs 150 crore. Bankers to the issue said that the promoters have reduced their selling stake marginally

Glenmark Lifesciences to double manufacturing capacity in five years

With formulation makers aiming at de-risk procurement by creating one more source for raw material other than China, the demand for APIs is rising, says company

Glenmark Life Sciences to open July 27 with 6.3 mn shares on sale

Anand Rathi Wealth files DRHP with Sebi, IPO will be pure offer for sale

Fitch affirms Glenmark Pharmaceuticals at BB with a stable outlook

Fitch Ratings has affirmed Glenmark Pharmaceuticals Ltd's long-term issuer default rating at BB with a stable outlook

Glenmark Pharma gets USFDA approval for generic lung cancer drug

Glenmark Pharmaceuticals said it has received approval from the US health regulator to market Nintedanib capsules, used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer

Glenmark Pharma gets US health regulator nod for inhalation product

Glenmark Pharma said it received approval from the US health regulator for Arformoterol Tartrate Inhalation Solution, used to treat conditions like chronic bronchitis and emphysema, in the US market

Glenmark Pharma releases interim data from PMS study on Favipiravir

Glenmark Pharmaceuticals announced interim data of 503 patients from its Post Marketing Surveillance (PMS) study on Favipiravir in India

Stocks to watch: GAIL, Bata India, Prestige Estates, Tata Motors, Glenmark

Reserve Bank of India granted approval for the re-appointment of Chandra Shekhar Ghosh, Managing Director & Chief Executive Officer of Bandhan Bank for a period of three years

Glenmark says interim data from study supports favipiravir's safety

A total of 13 sites across Mumbai, Bengaluru, Hyderabad, Nashik, Nagpur and Trivandrum took part in the study

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The medicines are a therapeutic equivalent of Banzel®

Drugmaker Glenmark fourth quarter net profit up 6% at Rs 233.87 crore

The rise came on account of higher sales.

Nifty Pharma index hits all-time high; Sun Pharma scales 4-year high

Since April, the Nifty Pharma index has outperformed the market by surging 15 per cent, against 1.7 per cent gain in the Nifty50 index

Glenmark Pharma hits 23-month high on Glenmark Life Sciences IPO plan

ICICI Securities believe this is a positive development for the company and will lead to value unlocking for the shareholder

Glenmark Pharma arm files paperwork for IPO with market regulator

Glenmark Pharmaceuticals on Saturday said its wholly-owned arm Glenmark Life Sciences has filed paperwork to go public

Domestic growth trajectory to remain strong for Glenmark in near term

Debt reduction key if the stock is to fetch higher valuation multiples

Glenmark gets USFDA nod for generic high blood pressure drug

Drug firmGlenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator for its generic Diltiazem Hydrochloride extended release capsules used for treatment of high blood pressure. The company has received final approval from the United States Food & Drug Administration (USFDA) for Diltiazem Hydrochloride extended-release capsules USP, in the strengths of 60 mg, 90 mg, and 120 mg, Glenmark said in a statement. The product is a generic version of Biovail Laboratories Inc's Cardizem SR extended-release capsules in the same strengths, it added. The company has been granted a competitive generic therapy (CGT) designation for these capsules, therefore, with thisapproval, Glenmark is eligible for 180 days of CGT exclusivity upon commercial marketing, the statementsaid. According to IQVIA sales data for the 12-month period ending January 2021, the Cardizem SR extended-release capsules, 60 mg, 90 mg, and 120 mg market (including brand and all available ...

Glenmark Pharma signs Rohit Sharma as brand ambassador for Candid Powder

Drug major Glenmark Pharma on Friday said it has signed cricketer Rohit Sharma as brand ambassador for its product Candid Powder.

Asset monetisation, sales uptick in US key triggers for Glenmark Pharma

The India business is expected to post double digit growth in FY22